SignaBlok to present favorable preclinical data on a first-in-class TREM-1 therapy for retinopathy of prematurity (ROP) at the 2026 Association for Research in Vision and Ophthalmology (ARVO) annual meeting

SignaBlok > News > SignaBlok to present favorable preclinical data on a first-in-class TREM-1 therapy for retinopathy of prematurity (ROP) at the 2026 Association for Research in Vision and Ophthalmology (ARVO) annual meeting

SignaBlok to present favorable preclinical data on a first-in-class TREM-1 therapy for retinopathy of prematurity (ROP) at the 2026 Association for Research in Vision and Ophthalmology (ARVO) annual meeting

Vera

View posts by Vera
Scroll to top